MRNA Moderna, Inc. Insider Trading

Stephen Hoge sells 53,336 MRNA shares at $67.60; stock now -26.2% from 52-week high amid -39.9% revenue decline

Stephen Hoge, Moderna's President, executed a scheduled sale of 53,336 shares at $67.60 on 2026-07-15 under a pre-arranged 10b5-1 trading plan adopted 2025-11-13, reducing his non-derivative holdings by 3.5% to 1,483,848 shares. The sale occurred as MRNA stock is down 26.2% from its 52-week high of $85.60, while the company reported a net loss of $-1.3B for the most recent full fiscal year and annual revenue declined 39.9% year-over-year. His prior five sales at MRNA show mixed timing outcomes: two recent 2026 sales (June and May) posted 30-day gains of 32.9% and 3.1%, respectively, but two 2024 sales resulted in 90-day declines of -51.9% and -50.6%. This transaction's execution through a scheduled 10b5-1 plan removes discretionary timing from consideration; investors should focus on the company's deteriorating financial profile—the net loss and sharp revenue contraction—rather than interpreting the sale as a timing signal.

Moderna President Hoge sold 53,336 shares ($2.7M) on 2026-06-15 via pre-arranged 10b5-1 plan; stock up 28.5% in 30 days post-sale.

Stephen Hoge, Moderna's President, sold 53,336 shares at $51.37 on 2026-06-15, reducing non-derivative holdings to 1,483,848 shares (a -3.5% reduction from 1,537,184 shares). This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-11-13, making it a scheduled divestment rather than a discretionary trade. Since the sale, MRNA has risen +28.5% over 30 days, trading at $61.80 (within 0.8% of its 52-week high of $62.30). Notably, Hoge's prior open-market trades across all tickers show a cross-ticker track record averaging -2.4% return 90 days after sells, and his MRNA-specific history includes five prior sales with mixed results, most recently a May 2026 sale that saw +3.1% gains in the following 30 days. The company's fundamentals remain challenged: Moderna generated revenue of $389,000,000.00 in the latest quarter but posted a net loss of $-1,343,000,000.00 for the full fiscal year, with annual revenue declining -39.9% year-over-year. The insider retains substantial derivative holdings (53,336 shares via stock options), meaning his overall economic exposure to MRNA remains material despite this partial non-derivative sale.

MRNA President Hoge sells 53,336 shares at $48.40; stock down 10.4% in 30 days, company lost $1.3B in last year.

Stephen Hoge, President of Moderna, sold 53,336 shares (53.3K shares) on 2026-05-15 at $48.40, reducing his holdings by 3.5% to 1.48M shares. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-11-13 and therefore represents a scheduled trade rather than a discretionary decision. The sale occurs against a backdrop of negative recent price momentum, with MRNA down 10.4% over the prior 30 days and trading 19.2% below its 52-week high of $59.55. More significantly, Moderna's fundamentals show deterioration: the company reported a net loss of $1.3B in its most recent full year and annual revenue declined 39.9% year-over-year, reflecting the sharp contraction in pandemic-related demand. His prior five trades at MRNA show mixed outcomes, including a notable 90-day loss of 51.9% following a July 2024 sale, but this current transaction is scheduled under a pre-arranged plan rather than a discretionary market response.

Moderna CLO Shannon Thyme sold 13,885 shares at $52.29 (10b5-1 plan execution)

Chief Legal Officer Shannon Thyme executed a sale of 13,885 shares at $52.29 on 2026-03-02 as part of a pre-arranged 10b5-1 trading plan adopted on 2025-09-09. This is a scheduled, non-discretionary transaction. Post-sale holdings total 59,689 shares, representing a -18.9% reduction versus pre-transaction holdings of 73,574 shares. Since the transaction is plan-governed rather than discretionary, the sale reflects a pre-established schedule rather than a current market or business judgment.

MRNA president Hoge sells 160,009 shares at $48.84 via pre-arranged 10b5-1 plan

Hoge Stephen, President of Moderna, sold 160,009 shares at $48.84 on 2026-02-23 under a 10b5-1 trading plan adopted on 2025-11-13, reducing his holdings from 1,617,436 shares to 1,457,427 shares. The sale represents a scheduled, predetermined transaction rather than a discretionary insider decision, limiting its value as a signal of current conviction or market outlook. Post-transaction holdings of 1,457,427 shares remain substantial, indicating continued significant equity exposure to the company. The pre-arranged plan structure means the timing and execution were determined months prior and do not reflect a contemporaneous assessment of valuation or business prospects.

Director Paul Sagan buys 31,620 MRNA shares at $31.76 as stock down -81.8% from 52-week high, -23.0% in 30 days.

Director Paul Sagan purchased 31,620 shares of Moderna at $31.76 on 2025-03-03, increasing his holdings from 280,407 to 312,027 shares. The transaction occurs in the context of significant recent weakness: the stock has fallen 81.8% from its 52-week high of $166.61 and declined 23.0% over the prior 30 days, closing today at $30.37. Moderna's fundamentals deteriorated substantially, with annual revenue declining 52.8% year-over-year and the company posting full-year negative net income, though the most recent quarter generated $13.0M in net income. The purchase represents an open-market acquisition by a director during a period of compressed valuation relative to the 52-week range, coinciding with a revenue-driven profitability reset in the business.

CEO Bancel acquires 160,314 shares for $5,004,318.13 as MRNA stock down 81.8% from 52-week high

On 2025-03-03, CEO Stephane Bancel purchased 160,314 shares across 2 transactions at a blended average price of $31.22, increasing his holdings to 9.21M shares. The timing is notable: the stock is currently trading at $30.37, down 81.8% from its 52-week high of $166.61 and down 23.0% over the past 30 days. Fundamentally, the company faces headwinds—annual revenue growth was -52.8%, and it remains unprofitable on a full-year basis despite recent quarterly revenue of $1.9B. Bancel's prior trade history at MRNA shows 4 of 5 prior sells were well-timed at the 90-day mark, suggesting he has demonstrated ability to read this specific stock. This purchase occurs in a sharply depressed price environment relative to recent highs, warranting close tracking of whether this represents confidence in a recovery or a miscalculation against continued deterioration.

Noubar Afeyan sells 15,000 MRNA shares for $1.8M under pre-arranged 10b5-1 plan

Noubar Afeyan, Director of Moderna, Inc., executed 4 separate sales totaling 15,000 shares for $1,799,442.81 on 2024-07-31, with transaction prices ranging from $118.96 to $121.62 and a blended average price of $119.96. This transaction was conducted pursuant to a pre-arranged 10b5-1 trading plan adopted on 2023-02-27, meaning it was scheduled and not discretionary. Post-transaction, Afeyan retained 2,224,015 shares (2.22M shares), representing a net reduction of 0.7% versus pre-transaction holdings of 2,239,015 shares (2.24M shares). The scheduled nature of this trade limits inference regarding current insider conviction or market views.

Director Afeyan sells 15,000 MRNA shares across 4 transactions for $1,766,972.01; holds 2.24M post-sale

Noubar Afeyan sold 15,000 shares (0.7% of pre-transaction holdings) on 2024-07-24 at a blended average price of $117.80, generating $1,766,972.01. This comes immediately after a series of five separate sales by the same director on 2024-07-17, suggesting sustained liquidation activity over consecutive trading days. Moderna's fundamentals show acute stress: the company reported negative net income of $-1.2B over its most recent full fiscal year, revenue of $167.0M in the latest quarter, and annual revenue growth of -64.4%, indicating a sharp decline in business traction. The stock currently trades at $122.11, modestly above the transaction prices but -26.7% from its 52-week high of $166.61. Afeyan's cross-ticker track record shows 20 prior sales with an average 90-day return of -4.5%, suggesting his recent sells at other companies have preceded declines; however, outcomes at MRNA specifically remain unmeasurable (the five prior MRNA sales from 2024-07-17 are too recent to assess 30- or 90-day performance).

Director Noubar Afeyan sold 15,000 shares for $1.8M under 10b5-1 plan adopted Feb 2023

Noubar Afeyan, Director of Moderna, executed 5 separate sales totaling 15,000 shares for $1,842,650.58 on 2024-07-17, with transaction prices ranging from $120.86 to $124.61 and a blended average of $122.84. This sale was executed under a pre-arranged 10b5-1 trading plan adopted on 2023-02-27, meaning it is scheduled rather than discretionary. Post-transaction holdings remain substantial at 2,254,015 shares, representing a reduction of only 0.7% from pre-transaction levels. The scheduled nature of this transaction precludes any inference about current conviction or market timing; it reflects a liquidity action authorized months in advance under regulatory safe-harbor provisions.